<DOC>
	<DOCNO>NCT01513460</DOCNO>
	<brief_summary>This study ass efficacy , tolerability safety NVA237 compare tiotropium add fluticasone/salmeterol patient chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Efficacy , Tolerability Safety NVA237 Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Patients Moderate Severe COPD ( Stage II Stage III ) accord GOLD 2010 guideline Current exsmokers smoke history least 10 pack year Qualifying FEV1 Visit 2 ( day 7 ) Patients history asthma history high blood eosinophil count ( &gt; 600/mm³ ) Patients concomitant pulmonary disease Patients lung lobectomy lung volume reduction lung transplantation Patients α1 antitrypsin deficiency Patients live attenuate vaccination within 30 day prior screen visit runin period Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease ,</keyword>
	<keyword>NVA 237 ,</keyword>
	<keyword>glycopyrronium ,</keyword>
	<keyword>COPD</keyword>
</DOC>